Neuroprotective therapy with age -related macular degeneration

Authors:
A.S. Vlasova1, S.A. Petrov1, 2, E.V. Renzyak1, 3

1anchoo DPO “West Siberian Institute of Postgraduate Medical Education”, Tyumen, Russia;
2FGBUN FIC "Tyumen Scientific Center of the Siberian Branch of the Russian Academy of Sciences", Tyumen, Russia;
3bu Khanty-Mansiysk Autonomous Okrug-Ugra District Clinical Hospital, Khanty-Mansiysk, Russia

Place of publication: Bulletin of ophthalmology / vol. 140, No. 6, 2024

Resume
age macular degeneration (VMD) is a chronic multifactorial degenerative disease of the eyes, which is considered one of the main causes of irreversible blindness around the world. Despite numerous studies, there is no consensus regarding the predominant pathological mechanism leading to the death of photoreceptors. The IDMD is a disease based on molecular and cellular disorders, ultimately leading to the degeneration of photoreceptors. The review article presents the data of foreign and domestic researchers on the study of pathophysiological mechanisms for the development and progression of photoreceptor degeneration, scientific developments are given in relation to modern methods of therapeutic correction of identified disorders, and also presents promising areas of drug neuroretinoprotection, requiring confirmation in clinical studies.

Keywords: age -related macular degeneration, neuroprotection, retinoprotection, peptide bioregulators, antioxidants, ethylmethylhydroxypirine succinate.

Information about the authors:
Vlasova A.S. -https://orcid.org/0000-0002-6835-3393
Petrov S.A. -https://orcid.org/0000-0002-1566-2299
Renzyak E.V. -https://orcid.org/0007-0007-2258-2207
Author responsible for correspondence: Vlasova Anastasia Sergeevna-E-mail: okula-83@mail.ru
How to quote:
Vlasova A.S., Petrov S.A., Renzyak E.V. Neuroprotective therapy for age -related macular degeneration. Bulletin of ophthalmology. 2024; 140 (6): 152–158. https://doi.org/10.17116/oftalma2024140061152